GlaxoSmithKline will apply for approval for its respiratory syncytial virus vaccine for older adults, after reporting data showing the shot is the first to work in the vulnerable age group for the major infectious disease.
葛兰素史克(GSK)将申请批准其针对老年人的呼吸道合胞病毒(RSV)疫苗。此前报告的数据显示，该疫苗是首个对这一主要传染病易感染人群发挥作用的疫苗。
您已阅读9%（297字），剩余91%（3078字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。